BACKGROUND: Inclusion of diverse groups of participants in cancer clinical trials is an important methodological and clinical issue. The quality of the science and generalizability of results depends on the inclusion of study participants who represent all populations among whom these treatment and prevention approaches will be used. METHODS: We conducted a systematic review using OVID as the primary source of reports included. Based on 304 peer-reviewed publications, diversity in the inclusion and reporting of study participants during a decade of cancer treatment and prevention trials (2001-2010) is summarized. Recommendations are made for improvements in the science and reporting of cancer clinical trials. RESULTS: Of the 277 treatment trials and 27 prevention trials included in this report, more than 80% of participants were white and 59.8% were male. In the recent decade, race and sex are rarely used as selection criteria unless the trial is focused on a sex-specific cancer. CONCLUSIONS: Women and racial/ethnic minorities remain severely underrepresented in cancer clinical trials, thus limiting the generalizability of cancer clinical research.
BACKGROUND: Inclusion of diverse groups of participants in cancer clinical trials is an important methodological and clinical issue. The quality of the science and generalizability of results depends on the inclusion of study participants who represent all populations among whom these treatment and prevention approaches will be used. METHODS: We conducted a systematic review using OVID as the primary source of reports included. Based on 304 peer-reviewed publications, diversity in the inclusion and reporting of study participants during a decade of cancer treatment and prevention trials (2001-2010) is summarized. Recommendations are made for improvements in the science and reporting of cancer clinical trials. RESULTS: Of the 277 treatment trials and 27 prevention trials included in this report, more than 80% of participants were white and 59.8% were male. In the recent decade, race and sex are rarely used as selection criteria unless the trial is focused on a sex-specific cancer. CONCLUSIONS:Women and racial/ethnic minorities remain severely underrepresented in cancer clinical trials, thus limiting the generalizability of cancer clinical research.
Authors: Melissa A Green; Margo Michaels; Natasha Blakeney; Adebowale A Odulana; Malika Roman Isler; Alan Richmond; Debra G Long; William S Robinson; Yhenneko J Taylor; Giselle Corbie-Smith Journal: J Cancer Educ Date: 2015-03 Impact factor: 2.037
Authors: Grace C Hillyer; Melissa Beauchemin; Dawn L Hershman; Moshe Kelsen; Frances L Brogan; Rossy Sandoval; Karen M Schmitt; Andria Reyes; Mary Beth Terry; Andrew B Lassman; Gary K Schwartz Journal: Clin Trials Date: 2020-02-03 Impact factor: 2.486
Authors: Jessica L Krok-Schoen; James L Fisher; Ryan D Baltic; Electra D Paskett Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-08-15 Impact factor: 4.254
Authors: Adebowale Odulana; Mimi M Kim; Melissa Green; Yhenneko Taylor; Daniel L Howard; Paul Godley; Giselle Corbie-Smith Journal: J Relig Health Date: 2014-04
Authors: Alannah L Phelan; Allen R Kunselman; Cynthia H Chuang; Nazia T Raja-Khan; Richard S Legro Journal: Diabetes Care Date: 2016-04-18 Impact factor: 19.112